- Home
- XGN vs CALC Comparison
XGN vs CALC Comparison
Compare XGN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- CALC
- Stock Information
- Founded
- XGN 2002
- CALC 2011
- Country
- XGN United States
- CALC United States
- Employees
- XGN N/A
- CALC N/A
- Industry
- XGN Medical Specialities
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- CALC Health Care
- Exchange
- XGN Nasdaq
- CALC Nasdaq
- Market Cap
- XGN 138.3M
- CALC 22.9M
- IPO Year
- XGN 2019
- CALC N/A
- Fundamental
- Price
- XGN $6.96
- CALC $1.64
- Analyst Decision
- XGN Strong Buy
- CALC Strong Buy
- Analyst Count
- XGN 2
- CALC 3
- Target Price
- XGN $7.50
- CALC $16.33
- AVG Volume (30 Days)
- XGN 227.1K
- CALC 28.9K
- Earning Date
- XGN 08-04-2025
- CALC 08-11-2025
- Dividend Yield
- XGN N/A
- CALC N/A
- EPS Growth
- XGN N/A
- CALC N/A
- EPS
- XGN N/A
- CALC N/A
- Revenue
- XGN $56,724,000.00
- CALC N/A
- Revenue This Year
- XGN $19.39
- CALC N/A
- Revenue Next Year
- XGN $13.27
- CALC N/A
- P/E Ratio
- XGN N/A
- CALC N/A
- Revenue Growth
- XGN 1.78
- CALC N/A
- 52 Week Low
- XGN $1.75
- CALC $1.42
- 52 Week High
- XGN $7.95
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- XGN 51.11
- CALC 49.89
- Support Level
- XGN $6.82
- CALC $1.59
- Resistance Level
- XGN $7.15
- CALC $1.69
- Average True Range (ATR)
- XGN 0.37
- CALC 0.15
- MACD
- XGN -0.06
- CALC 0.01
- Stochastic Oscillator
- XGN 25.56
- CALC 52.26
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.